Stock Analysis
Palvella Therapeutics, Inc. (PVLA) Stock Analysis
Palvella Therapeutics, Inc. (PVLA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Palvella Therapeutics, Inc. (PVLA) currently has an AIQ Score of 70/100, indicating a bullish setup. Momentum is the strongest factor at 84/100. Risk is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
PVLA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $152.48 |
| AIQ Score | 70/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Buy |
| Market Cap | $2.22B |
| P/E Ratio (TTM) | -27.72 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.70 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.65 |
| Volume | 241.73K |
| 52-week range | $72.23-$179.95 |
| RSI 14 | 52.57 |
| 50-Day SMA | $143.56 |
| 200-Day SMA | $130.44 |
| Analyst Price Target | $237.33 |
| Next Earnings | — |
PVLAPalvella Therapeutics, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum84
- Value—
- Quality65
- Risk resilience47
- Sentiment—
PVLA Stock Analysis Summary
Palvella Therapeutics, Inc. (PVLA) currently has an AIQ Score of 70/100, indicating a bullish setup. Momentum is the strongest factor at 84/100. Risk resilience is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, PVLA has AIQ Score of 70/100 with Momentum base of 84/100 and fading Risk resilience at 47/100. Wait for component alignment before adding exposure.
Momentum (84/100) leads while Risk resilience (47/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.46% stock move · PVLA classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is PVLA Bullish or Bearish Right Now?
PVLA currently has a bullish overall setup. Momentum is the strongest factor at 84/100, while Risk Resilience is weakest at 47/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 65/100.
- - Momentum is constructive at 84/100.
- - Price is +6.22% above its 50-day SMA.
- - Analyst target implies +55.65% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (29 vs 10).
- - Risk Resilience is weak at 47/100.
Current Consensus
PVLA's Technical Analysis Consensus is currently Buy, with 29 buy, 7 neutral, and 10 sell votes. PVLA's 14-day RSI is 52.57, which places the stock in a neutral momentum range. PVLA's beta is 1.65, indicating greater market sensitivity than the broad market.
What Changed in PVLA?
The largest recent change in PVLA is Momentum moving up by 5.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the PVLA Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
PVLA Decision Framework
Public evidence layers, setup checks, and risk context for Palvella Therapeutics, Inc..
Palvella Therapeutics, Inc. (PVLA) Stock Analysis
Palvella Therapeutics, Inc. has an AIQ Score of 70/100 in a Bullish regime. Momentum is strongest at 84/100. Beta is 1.65, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | PVLA is in a Bullish AIQ regime with score 70/100. |
| Signal Conflict | The primary conflict is that momentum leads at 84/100 while risk lags at 47/100. |
| Factor Evidence | Momentum 84/100 · Quality 65/100 · Risk 47/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 84/100.
Momentum is 84/100 and RSI (14) is 52.6.
PVLA is in a Bullish regime at 70/100.
Risk factor is 47/100 with beta 1.65 and annual volatility 84.47%.
Current conflict: momentum leads at 84/100 while risk lags at 47/100.
PVLA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
PVLA Fundamentals
PVLA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
PVLA Technical Analysis
PVLA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
PVLA Stock Catalysts
Track PVLA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
PVLA Dividend Analysis
PVLA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
PVLA Financial Data
PVLA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
PVLA Risk Analysis
PVLA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
PVLA Stock News
PVLA stock news, market tone, recent headlines, and catalyst context.
PVLA vs Biotechnology Peers
Current peer cohort: PVLA · QURE · RAPP · RCUS · REPL. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| PVLA Current stock | 70/100 | — | 84/100 | 47/100 | 1.12 | 84.47% | Current |
| QURE uniQure N.V. | 39/100 | 38/100 | 41/100 | 31/100 | 0.39 | 132.25% | PVLA vs QURE |
| RAPP Rapport Therapeutics, Inc. Common Stock | 43/100 | 42/100 | 33/100 | 39/100 | 0.35 | 62.34% | PVLA vs RAPP |
| RCUS Arcus Biosciences, Inc. | 39/100 | 43/100 | 34/100 | 42/100 | 0.05 | 62.65% | PVLA vs RCUS |
| REPL Replimune Group, Inc. | 60/100 | — | 97/100 | 26/100 | 1.3 | 187.93% | PVLA vs REPL |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for PVLA: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching PVLA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for PVLA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
PVLA Stock FAQ
What is PVLA stock price today?
Palvella Therapeutics, Inc.'s current stock price is $152.48. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is PVLA bullish or bearish right now?
PVLA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is PVLA's market cap?
PVLA's market cap is $2.22B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is PVLA's current P/E ratio?
PVLA's current P/E ratio is -27.72 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is PVLA's RSI?
PVLA's 14-day RSI is 52.57 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is PVLA above its 50-day and 200-day moving averages?
PVLA is 6.22% from its 50-day SMA and 16.90% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is PVLA's next earnings date?
PVLA's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does PVLA pay a dividend?
PVLA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.